About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
We are dedicated to investigate transfusional activity, the alteration of erythrocytes during the conservation period and extracorporeal photoapheresis. We work on the molecular and serological characterization of blood group variants. In non-invasive fetal genotyping strategies due to blood group incompatibilities. We develop iPSC lines and produce in vitro erythrocytes with rare phenotypes. We deepen in the knowledge of epidemiology and the detection of infectious agents relevant for safety of the products supplied by the Blood and Tissue Bank.
We investigate in clinical immunology and develop our own HLA and KIR typing protocols. We develop and incorporate new therapeutic applications in cell therapy including hematopoietic transplantation, cellular immunology and regenerative medicine. We investigate the molecular mechanisms and genotype-phenotype correlation of coagulopathies, haemorrhagic diathesis and other associated congenital pathologies. We develop tools based on the new technologies of parallel massive sequencing with application to the molecular study, genetic counselling and prenatal diagnosis.
Epidemiology and detection of infectious agents relevant for the safety of the products supplied by the Blood and Tissue Bank.
PI: Piron, Maria
Researchers:
Casamitjana Ponces, Natàlia
Researchers in training:
De la Torre Rial, Carmen
IP: -
Development and incorporation of new therapeutic applications in the area of ??cell therapy including hematopoietic transplantation, cellular immunology and regenerative medicine.
PI: Querol Giner, Sergi
García Gómez, Susana
Rodríguez Gómez, Luciano
Samarkanova, Dinara
Enrich Randés, Emma
Lopez Montañes, Maria
Nursing, technical and administrative staff:
Ribo, Nuria
Investigation in the molecular mechanisms and the genotype-phenotype correlation of coagulopathies, hemorrhagic diathesis and other associated congenital pathologies. Development of tools based on the new technologies of parallel massive sequencing with application to the molecular study, genetic counselling and prenatal diagnosis.
PI: Parra López, Rafael and Vidal Pérez, Francisco
Corrales Insa, Irene
Altisent Roca, Carme
Researcher in training:
Borrás Agustí, Nina
Ramírez Orihuela, Lorena
Comes Fernández, Natalia
Garcia, Iris
IP: Rafael Parra López, Francisco Vidal Pérez
Clinical immunology and development of our own HLA and KIR typing protocols.
PI: Herrero Mata, María José
Caro Oleas, José Luís
Rudilla Salvador, Francesc
Enrich Randé, Emma
Grau Vorster, Marta
Closa Gil, Laia
IP: Maria Jose Herrero Mata
IP: Irene Corrales Insa Collaborators: Olga Benitez Hidalgo, Francisco Vidal Pérez, Rafael Parra López, Lorena Ramirez Orihuela, Iris Garcia Martínez, Carlos Hobeich Naya, Laura Martin Fernandez, Nina Borràs Agustí, Natàlia Comes Fernández Funding agency: Instituto de Salud Carlos III Funding: 177500 Reference: PI23/01672 Duration: 01/01/2024 - 31/12/2026
PhD student: Jesus Fernandez Sojo Director/s: Sergi Querol Giner University: Universitat de Barcelona Year: 2023
PhD student: Dinara Samarkanova , Dinara Samarkanova , Dinara Samarkanova Director/s: Sergi Querol Giner University: Universidad Autònoma de Barcelona Year: 2020
PhD student: Daniel Chaverri Fierro, Daniel Chaverri Fierro Director/s: Juan Minguell Moñart, Joaquim Vives Armengol University: Universidad Autònoma de Barcelona Year: 2019
PhD student: Nerea Castillo Flores, Nerea Castillo Flores, Nerea Castillo Flores Director/s: Sergi Querol Giner University: Universidad Autònoma de Barcelona Year: 2017
PhD student: Margarita Codinach Creus Director/s: César Galo García Fontecha, Joaquim Vives Armengol University: Universidad Autònoma de Barcelona Year: 2015
PhD student: Ester Canto Puig Director/s: Manuel Comabella Lopez, Xavier Montalban Gairín, Xavier Montalban Gairín University: Universidad Autònoma de Barcelona Year: 2014
PhD student: Irene Corrales Insa Director/s: Francisco Vidal Pérez University: Universitat de Barcelona Year: 2011
PhD student: Cecilia González Santesteban, Cecilia González Santesteban Director/s: University: Universidad Autònoma de Barcelona Year: 2009
Over time, wild boars have approached the city of Barcelona and surrounding areas. As carriers of the hepatitis E virus, they are linked to a study identifying them as a potential source of transmission of this disease.
